Zacks Investment Research Upgrades InflaRx (NASDAQ:IFRX) to “Buy”

InflaRx (NASDAQ:IFRXGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The brokerage presently has a $1.75 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 19.05% from the company’s previous close.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

Several other equities analysts have also issued reports on the company. HC Wainwright reduced their target price on InflaRx from $10.00 to $7.00 in a report on Friday, May 13th. Guggenheim lowered InflaRx from a “buy” rating to a “neutral” rating in a report on Monday, February 28th. SVB Leerink reduced their price objective on InflaRx from $8.00 to $6.00 and set an “outperform” rating for the company in a report on Friday, March 25th. Finally, Raymond James reduced their price objective on InflaRx from $15.00 to $7.00 in a report on Friday, May 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, InflaRx has a consensus rating of “Buy” and a consensus target price of $4.85.

Shares of IFRX stock traded down $0.10 during trading on Friday, hitting $1.47. The company’s stock had a trading volume of 28,774 shares, compared to its average volume of 216,453. The company has a market cap of $64.98 million, a PE ratio of -1.04 and a beta of 0.82. The business has a fifty day moving average of $1.66 and a 200-day moving average of $2.97. InflaRx has a 52 week low of $1.29 and a 52 week high of $5.69.

InflaRx (NASDAQ:IFRXGet Rating) last released its earnings results on Thursday, March 24th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.04. On average, sell-side analysts expect that InflaRx will post -1.32 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP bought a new position in shares of InflaRx in the third quarter worth $29,000. Commonwealth Equity Services LLC bought a new position in shares of InflaRx in the fourth quarter worth $48,000. Geode Capital Management LLC bought a new position in shares of InflaRx in the third quarter worth $49,000. Virtu Financial LLC bought a new position in shares of InflaRx in the first quarter worth $53,000. Finally, Two Sigma Securities LLC bought a new position in shares of InflaRx in the third quarter worth $58,000. 20.98% of the stock is owned by hedge funds and other institutional investors.

InflaRx Company Profile (Get Rating)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.

See Also

Get a free copy of the Zacks research report on InflaRx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.